Download PDF
Thromb Haemost 1986; 55(01): 037-039
DOI: 10.1055/s-0038-1661442
Original Article
Schattauer GmbH Stuttgart

Heparin-Associated Thrombocytopenia Treatment with Low Molecular Weight Heparin

Jean-F Vitoux
*   The Chaire de Clinique Médicale et de Pathologie Vasculaire, Hôpital Broussais,Paris, France
,
Jean-F Mathieu
**   The Service de Chirurgie Vasculaire, Hôpital Saint Joseph, Paris, France
,
Martine Roncato
***   The Laboratoire d’Hémostase, Hôpital Broiissais, Paris, France
,
Jean-N Fiessinger
*   The Chaire de Clinique Médicale et de Pathologie Vasculaire, Hôpital Broussais,Paris, France
,
Martine Aiach
***   The Laboratoire d’Hémostase, Hôpital Broiissais, Paris, France
› Author Affiliations
Further Information

Publication History

Received 17 January 1985

Accepted 14 October 1985

Publication Date:
19 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Eight patients with heparin associated thrombocytopenia (HAT) were treated by a low molecular weight heparin derivative (LMW). Biological and clinical improvement occurred in all patients. This efficiency confirms the antithrombotic activity of LMW and allows its use in patients with HAT.

Key words

Heparin-associated thrombocytopenia - Thrombus formation - Low molecular weight heparin
 

  • References

  • 1 Babcock RB, Dumper CW, Scharfman WB. Heparin-induced immune thrombocytopenia. N Engl J Med 1976; 295: 237-241
    CrossrefPubMedGoogle Scholar
  • 2 Bell WR. Thrombocytopenia occurring during heparin therapy. N Engl J Med 1976; 295: 276-277
    CrossrefPubMedGoogle Scholar
  • 3 Hrushesky WJ. Subcutaneous heparin-induced thrombocytopenia. Arch Intern Med 1978; 138: 1489-1491
    CrossrefPubMedGoogle Scholar
  • 4 Kapsch DN, Adelstein EH, Rhodes GR, Silver D. Heparin-induced thrombocytopenia, thrombosis and hemorrhage. Surgery 1979; 86: 148-155
    PubMedGoogle Scholar
  • 5 King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100: 535-540
    CrossrefPubMedGoogle Scholar
  • 6 Kitzis M, Huisse MG, Hannoun L, Couffinhal JC, Dusaintpere C, Andreassian B. Thrombopénies induites par l’héparine. Diagnostic biologique et complications. Arch Mai Coeur 1980; 73: 1395-1404
    PubMedGoogle Scholar
  • 7 Nelson JC, Lerner RG, Goldstein R, Cagin NA. Heparin-induced thrombocytopenia. Arch Intern Med 1978; 138: 548-552
    CrossrefPubMedGoogle Scholar
  • 8 Powers PJ, Kelton JG, Carter CJ. Studies on the frequency of heparin associated thrombocytopenia. Thromb Res 1984; 33: 439-443
    CrossrefPubMedGoogle Scholar
  • 9 Ramirez-Lassepas M, Cipolle RJ. Heparin and thrombocytopenia. Ann Intern Med 1984; 100: 613
    PubMedGoogle Scholar
  • 10 Baird RA, Convery FR. Arterial thromboembolism in patients receiving systemic heparin therapy. J Bone Joint Surg (Am) 1977; 59 A: 1061-1064
    CrossrefPubMedGoogle Scholar
  • 11 Kapsch DN, Silver D. Heparin-induced thrombocytopenia with thrombosis and hemorrhage. Arch Surg 1981; 116: 1423-1427
    CrossrefPubMedGoogle Scholar
  • 12 Rhodes GR, Dixon RH, Silver D. Heparin-induced thrombocytopenia: Eight cases with thrombotic-hemorrhagic complications. Ann Surg 1977; 186: 752-758
    CrossrefPubMedGoogle Scholar
  • 13 Roussi JH, Houbouyan LL, Goguel AF. Use of low molecular weight heparin-induced thrombocytopenia with thrombotic complications. Lancet 1984; 8387: 1183
    PubMedGoogle Scholar
  • 14 Trono DP, Kaelin RM, Thonney JL, Vader JP. Thrombocytopenia and heparin associated thrombosis. Ann Intern Med 1984; 100: 464-465
    PubMedGoogle Scholar
  • 15 Aiach M, Michaud A, Balian JL, Lefebvre M, Woler M, Fourtillan J. A new low molecular weight heparin derivative, in vitro and in vivo studies. Thromb Res 1983; 31: 611-621
    CrossrefPubMedGoogle Scholar
  • 16 Hisse MG, Guillin MC, Bezeaud A, Toulemonde F, Kitzis M, Andreassian B. Heparin-associated thrombocytopenia. In vitro effects of different molecular weight heparin fractions. Thromb Res 1982; 27: 485-490
    CrossrefPubMedGoogle Scholar
  • 17 Follea G, Mandrand B, Dechavanne M. Simultaneous enzymo-immunologic assays of platelet associated IgG, IgM and C3. A useful tool in assessment of immune thrombocytopenias. Thromb Res 1982; 26: 249-258
    CrossrefPubMedGoogle Scholar
  • 18 Harenberg J, Zimmermann R, Schwarz F, Kubler W. Treatment of heparin-induced thrombocytopenia with thrombosis by new heparinoid. Lancet 1983; 8331: 986-987
    PubMedGoogle Scholar
  • 19 Horellou MH, Conard J, Lecrubier C, Samama M, Roque-d’Orbcas-tel O, Fenoyl Ode, Di Maria G, Bernadou A. Persistent heparin induced thrombocytopenia despite therapy with low molecular weight heparin. Thromb Haemostas 1984; 51: 134-135
    PubMedGoogle Scholar
  • 20 Kelton JG, Sheridan D, Brain H, Powers PJ, Turpie AG, Carter CJ. Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia. J Lab Clin Med 1984; 103: 606-612
    PubMedGoogle Scholar
  • 21 Aiach M, Dreyfus G, Michaud A, Relland J, Murawski M, Leclerc M, Carpentier A. Low Molecular Weight (LMW) Heparin Derivatives in Experimental Extra Corporeal Circulation (ECC). Haemostasis 1984; 14: 325-332
    PubMedGoogle Scholar